Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 18/20 | 0.59 |
| ▸ | BRD2 | P25440 | 3/20 | 0.45 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16697371 | 0.91 | BRD4 (0.56) | BRD4BRD2CREBBP | |
| SCHEMBL16697023 | 0.91 | BRD4 (0.51) | BRD4BRD2 | |
| SCHEMBL16697140 | 0.89 | BRD4 (0.69) | BRD4BRD2 | |
| SCHEMBL16696893 | 0.88 | BRD4 (0.60) | BRD4BRD2CREBBP | |
| SCHEMBL16696710 | 0.87 | BRD4 (0.47) | BRD4BRD2 | |
| SCHEMBL16697074 | 0.87 | BRD4 (0.65) | BRD4BRD2CREBBP | |
| SCHEMBL19183777 | 0.86 | BRD4 (0.58) | BRD4BRD2CREBBP | |
| SCHEMBL16697571 | 0.85 | BRD4 (0.57) | BRD4BRD2CREBBPPTGDR2 | |
| SCHEMBL16697112 | 0.84 | BRD4 (0.51) | BRD4BRD2 | |
| SCHEMBL16697527 | 0.84 | BRD4 (0.61) | BRD4BRD2CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170320899-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PLEXXIKON INC. (US) | 2017-11-09 | — | — | US | disclosed |
| US-20170320899-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PLEXXIKON INC. (US) | 2017-11-09 | — | — | US | disclosed |
| US-20170320899-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PLEXXIKON INC. (US) | 2017-11-09 | — | — | US | disclosed |
| US-9718847-B2 | Heterocyclic compounds and uses thereof | PLEXXIKON INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-9718847-B2 | Heterocyclic compounds and uses thereof | PLEXXIKON INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-9718847-B2 | Heterocyclic compounds and uses thereof | PLEXXIKON INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-20150133400-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Opna Bio SA (CH) | 2015-05-14 | — | — | US | disclosed |
| US-20150133400-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Opna Bio SA (CH) | 2015-05-14 | — | — | US | disclosed |
| US-20150133400-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Opna Bio SA (CH) | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133400-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | CYP11B2, CYP11B1, CYP2C19 | BRD4 1365/4885BRD2 2805/4885CREBBP 1261/4885 |
| US-20170320899-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | CYP11B2, CYP11B1, CYP2C19 | BRD4 1365/4885BRD2 2805/4885CREBBP 1261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.